Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy

被引:66
作者
Gardulf, A. [1 ]
Borte, M. [2 ,3 ]
Ochs, H. D.
Nicolay, U. [1 ,4 ,5 ]
机构
[1] Karolinska Univ Hosp Huddinge, Karolinska Inst, Clin Immunol Sect, Dept Lab Med, SE-14186 Stockholm, Sweden
[2] Childrens Hosp, Municipal Hosp St Georg Leipzig, Leipzig, Germany
[3] Univ Leipzig, Dept Pediat, Leipzig, Germany
[4] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA
[5] Childrens Hosp & Reg Med Ctr, Seattle, WA 98195 USA
关键词
primary immunodeficiency disorders; immunoglobulin; subcutaneous IgG infusions; quality of life; treatment satisfaction; self-care; home therapy;
D O I
10.1016/j.clim.2007.06.009
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The aims of the present study were to evaluate the health-related quality of life (HRQL) and treatment satisfaction (TS) of adults and children with primary antibody deficiencies (PAD) before and after the introduction of subcutaneous immunoglobulin G (SCIG) self-infusions at home and to identify prognostic factors (demographic/social, medical, patient/parent reported) for HRQL. 85 adults and 21 parents of children with PAD answered the SF-36 (adults), CHQ-PF50 (parents), and the LQI (adults and parents) at baseline and following 10 months of weekly self-administered SCIG infusions at home. The SCIG home therapy was associated with significant improvements in HRQL and TS, particularly in patients who had previously received IVIG therapy in hospital settings. Background factors that were found to be associated with HRQL changes in adults were age, serum IgG levels at month 10, concomitant joint/muscle/skeletal disorders, clinical study location and smoking status. (C) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:81 / 88
页数:8
相关论文
共 41 条
[1]  
Abrahamsen TG, 1996, PEDIATRICS, V98, P1127
[2]   USE OF INTRAVENOUS GAMMA-GLOBULIN IN ANTIBODY IMMUNODEFICIENCY - RESULTS OF A MULTI-CENTER CONTROLLED TRIAL [J].
AMMANN, AJ ;
ASHMAN, RF ;
BUCKLEY, RH ;
HARDIE, WR ;
KRANTMANN, HJ ;
NELSON, J ;
OCHS, H ;
STIEHM, ER ;
TILLER, T ;
WARA, DW ;
WEDGWOOD, R .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1982, 22 (01) :60-67
[3]  
[Anonymous], 1999, Child health questionnaire (CHQ): a user's manual
[4]   Subcutaneous immunoglobulin replacement in primary immunodeficiencies [J].
Berger, M .
CLINICAL IMMUNOLOGY, 2004, 112 (01) :1-7
[5]  
Brown H., 1999, Applied mixed models in medicine
[6]  
BRUTON OC, 1952, PEDIATRICS, V9, P722
[7]  
Buckley Rebecca H, 2004, Paediatr Respir Rev, V5 Suppl A, pS225, DOI 10.1016/S1526-0542(04)90043-7
[8]  
BUCKLEY RH, 1991, NEW ENGL J MED, V325, P110, DOI 10.1056/NEJM199107113250207
[9]   Primary immunodeficiency diseases: dissectors of the immune system [J].
Buckley, RH .
IMMUNOLOGICAL REVIEWS, 2002, 185 :206-219
[10]   The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy [J].
Chapel, HM ;
Spickett, GP ;
Ericson, D ;
Engl, W ;
Eibl, MM ;
Bjorkander, J .
JOURNAL OF CLINICAL IMMUNOLOGY, 2000, 20 (02) :94-100